Keyphrases
Additional Treatment
14%
Adverse Events
42%
Antibiotic Resistance
100%
Bacterial Eradication
14%
Bacterial Pathogens
33%
Besifloxacin
100%
Between-group
14%
Clinical Centers
14%
Corneal Neovascularization
14%
Corneal Scar
14%
Event Frequency
14%
Eye Surgery
33%
Microbial Keratitis
100%
Moxifloxacin
14%
Ophthalmic Solutions
14%
Ophthalmic Suspension
100%
Pain Duration
14%
Post-marketing Surveillance
14%
Postoperative Endophthalmitis
100%
Prospective Clinical Trial
14%
Retrospective Data
14%
Risk Factors
33%
Safety Information
14%
Safety Surveillance
100%
Serious Adverse Events
14%
Superficial Punctate Keratitis
14%
Surveillance Studies
100%
Therapeutic Outcome
14%
Treatment Outcome
28%
United States
14%
Visual Acuity
14%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
57%
Agents Acting on the Eye
100%
Antibiotic Resistance
100%
Bacterial Clearance
14%
Bacterial Keratitis
100%
Besifloxacin
100%
Clinical Trial
14%
Cornea Neovascularization
14%
Endophthalmitis
100%
Eye Drops
14%
Infectious Agent
33%
Moxifloxacin
14%
Population Study
14%
Postmarketing Surveillance
14%
Punctate Keratitis
14%
Scar Formation
14%
Medicine and Dentistry
Antibiotic Prophylaxis
33%
Antibiotic Resistance
100%
Eye Surgery
33%
Health Care Cost
33%
Pathogen
33%
Postoperative Endophthalmitis
100%